Tectonic Therapeutic (TECX) Net Income towards Common Stockholders (2017 - 2026)
Tectonic Therapeutic (TECX) has 10 years of Net Income towards Common Stockholders data on record, last reported at -$25.2 million in Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 58.69% to -$25.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$83.5 million, a 42.3% decrease, with the full-year FY2025 number at -$74.2 million, down 27.89% from a year prior.
- Net Income towards Common Stockholders reached -$25.2 million in Q1 2026 per TECX's latest filing, down from -$19.2 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for TECX hit a ceiling of $67.5 million in Q2 2023 and a floor of -$29.8 million in Q1 2022.
- A 5-year average of -$14.0 million and a median of -$19.0 million in 2025 define the central range for Net Income towards Common Stockholders.
- Peak YoY movement for Net Income towards Common Stockholders: skyrocketed 340.52% in 2023, then plummeted 118.78% in 2024.
- Tracing TECX's Net Income towards Common Stockholders over 5 years: stood at -$25.0 million in 2022, then skyrocketed by 68.57% to -$7.9 million in 2023, then plummeted by 57.24% to -$12.4 million in 2024, then crashed by 55.39% to -$19.2 million in 2025, then plummeted by 31.29% to -$25.2 million in 2026.
- Business Quant data shows Net Income towards Common Stockholders for TECX at -$25.2 million in Q1 2026, -$19.2 million in Q4 2025, and -$19.0 million in Q3 2025.